GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » North China Pharmaceutical Co Ltd (SHSE:600812) » Definitions » EV-to-EBITDA

North China Pharmaceutical Co (SHSE:600812) EV-to-EBITDA : 27.77 (As of May. 26, 2024)


View and export this data going back to 1994. Start your Free Trial

What is North China Pharmaceutical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, North China Pharmaceutical Co's enterprise value is ¥18,626 Mil. North China Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥671 Mil. Therefore, North China Pharmaceutical Co's EV-to-EBITDA for today is 27.77.

The historical rank and industry rank for North China Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:

SHSE:600812' s EV-to-EBITDA Range Over the Past 10 Years
Min: -717.72   Med: 32.32   Max: 3939.87
Current: 27.77

During the past 13 years, the highest EV-to-EBITDA of North China Pharmaceutical Co was 3939.87. The lowest was -717.72. And the median was 32.32.

SHSE:600812's EV-to-EBITDA is ranked worse than
79.58% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.42 vs SHSE:600812: 27.77

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), North China Pharmaceutical Co's stock price is ¥4.96. North China Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.011. Therefore, North China Pharmaceutical Co's PE Ratio for today is 450.91.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


North China Pharmaceutical Co EV-to-EBITDA Historical Data

The historical data trend for North China Pharmaceutical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

North China Pharmaceutical Co EV-to-EBITDA Chart

North China Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.17 18.91 20.16 26.16 13.58

North China Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,743.64 -701.46 -367.20 13.58 28.68

Competitive Comparison of North China Pharmaceutical Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, North China Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


North China Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, North China Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where North China Pharmaceutical Co's EV-to-EBITDA falls into.



North China Pharmaceutical Co EV-to-EBITDA Calculation

North China Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=18626.055/670.655
=27.77

North China Pharmaceutical Co's current Enterprise Value is ¥18,626 Mil.
North China Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥671 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


North China Pharmaceutical Co  (SHSE:600812) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

North China Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.96/0.011
=450.91

North China Pharmaceutical Co's share price for today is ¥4.96.
North China Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.011.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


North China Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of North China Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


North China Pharmaceutical Co (SHSE:600812) Business Description

Traded in Other Exchanges
N/A
Address
No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
Executives
Gao Ren Long senior management
Lian Fa Zhe Director

North China Pharmaceutical Co (SHSE:600812) Headlines

No Headlines